• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Viatris Inc.

    12/6/24 5:20:53 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email
    8-K
    Viatris Inc false 0001792044 0001792044 2024-12-06 2024-12-06

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 6, 2024

     

     

    VIATRIS INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39695   83-4364296

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317

    (Address of Principal Executive Offices)

    Registrant’s telephone number, including area code: (724) 514-1800

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.01 per share   VTRS   The NASDAQ Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02(e)

    Approval of an amendment to the Viatris Inc. 2020 Stock Incentive Plan.

    On December 6, 2024, Viatris Inc. (“Viatris” or the “Company”) held its 2024 annual meeting of shareholders (the “2024 Annual Meeting”). As further discussed below, at the 2024 Annual Meeting, shareholders of the Company approved an amendment to the Company’s 2020 Stock Incentive Plan (the “2020 Stock Incentive Plan Amendment”). For a description of the 2020 Stock Incentive Plan Amendment, see the Company’s Definitive Proxy Statement on Schedule 14A (File No. 001-39695), filed with the Securities and Exchange Commission on October 25, 2024 (the “Proxy Statement”). A copy of the 2020 Stock Incentive Plan Amendment is attached as Appendix C to such Proxy Statement.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    (a) On December 6, 2024, the Company held its 2024 Annual Meeting to (i) elect twelve director nominees, each to hold office until the 2025 annual meeting of shareholders; (ii) approve, on a non-binding advisory basis, the 2023 compensation of the named executive officers of the Company; (iii) ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; and (iv) approve the 2020 Stock Incentive Plan Amendment to (1) increase the maximum aggregate number of shares of Viatris common stock reserved and available for issuance for awards pursuant to the 2020 Stock Incentive Plan by 49,000,000 shares, subject to adjustment as provided in the Company’s 2020 Stock Incentive Plan, and (2) eliminate an exception to the 12-month minimum vesting requirement for awards granted on an ad hoc basis in order to achieve a specified business objective. With respect to each proposal below, any abstentions and broker non-votes were considered for purposes of establishing a quorum but were not considered to be votes cast and therefore had no effect on the vote on any such proposal.

     

    (b)

    The certified results of the matters voted on at the 2024 Annual Meeting are set forth below.

    Proposal No. 1 - Election of the following twelve director nominees, each to hold office until the 2025 annual meeting of shareholders:

     

    Nominee

       For      Against      Abstain      Broker Non-Votes  

    W. Don Cornwell

         900,964,555        4,460,343        3,834,109        114,954,301  

    JoEllen Lyons Dillon

         737,759,209        167,733,463        3,766,345        114,954,291  

    Elisha Finney

         902,054,026        3,436,873        3,768,120        114,954,291  

    Leo Groothuis

         878,504,023        26,933,798        3,821,197        114,954,291  

    Melina Higgins

         804,442,071        101,065,484        3,751,463        114,954,291  

    James M. Kilts

         840,616,779        64,831,995        3,810,242        114,954,293  

    Harry Korman

         780,276,345        125,203,030        3,779,642        114,954,292  

    Rajiv Malik

         823,760,959        81,491,917        4,006,144        114,954,289  

    Richard Mark

         900,441,821        5,011,531        3,805,662        114,954,295  

    Mark Parrish

         850,985,723        54,462,270        3,811,027        114,954,289  

    Scott A. Smith

         902,081,653        3,373,699        3,803,668        114,954,288  

    Rogério Vivaldi Coelho

         900,799,052        4,645,816        3,814,152        114,954,289  

    Each director nominee was elected to hold office until the 2025 annual meeting of shareholders.

    Proposal No. 2 – Approval, on a non-binding advisory basis, of the 2023 compensation of the named executive officers of the Company:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    445,035,979   458,870,163   5,352,861   114,954,306


    This proposal was not approved, but received 49.23% of votes in favor (thus missing approval by less than 0.80%).

    Proposal No. 3 – Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    962,950,848   54,384,649   6,877,812   N/A

    This proposal was approved.

    Proposal No. 4 – Approval of the 2020 Stock Incentive Plan Amendment:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    872,421,538   31,280,303   5,557,159   114,954,308

    This proposal was approved.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        VIATRIS INC.
    Date: December 6, 2024     By:  

    /s/ Theodora Mistras

          Theodora Mistras
          Chief Financial Officer
    Get the next $VTRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    4/24/2023$11.00Overweight → Equal Weight
    Barclays
    2/17/2023$16.00 → $14.00Outperform → Market Perform
    BMO Capital Markets
    1/27/2023$13.00 → $15.00Hold → Buy
    Jefferies
    11/10/2022$9.00 → $12.00Sell → Neutral
    UBS
    More analyst ratings